InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-901: A Promising New Candidate for Alzheimer’s Therapy
- INM-901 oral formulation shows encouraging results in preclinical studies
- High bioavailability of INM-901 oral formulation was shown to provide similar drug concentration levels in the brain as intraperitoneal injection
- Oral delivery method offers advantages such as lower treatment costs, in comparison with intravenous delivery of large molecule antibody therapies
- The company is conducting further research including drug metabolism studies, dose ranging studies and pharmacokinetic studies
InMed Pharmaceuticals (NASDAQ: INM), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors, announced that its drug candidate INM-901 as an oral formulation will be used in its development programs for Alzheimer’s disease following encouraging results obtained in preclinical trials (https://nnw.fm/xJETf ).
INM-901 is a small molecule drug candidate that demonstrated multiple pharmacological effects in preclinical studies including neuroprotective effects, extending the length of neurites which is important for brain cell-to-cell communication, as well as reducing neuroinflammation. These preclinical studies were conducted in well-characterized study models of Alzheimer’s disease.
Recent preclinical studies further showed that INM-901 can be administered orally, with the same therapeutic effects in the brain as intraperitoneal injections. INM-901 oral formulation was shown to maintain similar drug exposure levels as intraperitoneal injections over a 24-hour period. Oral delivery offers multiple advantages, including an overall reduction in treatment delivery costs compared to intravenous delivery of large molecule antibody therapies currently administered in such cases.
Large molecule antibody therapies are difficult to formulate orally and also present significant challenges to gastrointestinal tract absorption and further blood stream delivery, which is why IV or subcutaneous delivery methods need to be used instead. Additionally, large molecule therapies come with significant side effects, such as brain inflammation and bleeding, which requires constant monitoring and regular brain scans.
InMed Pharmaceuticals is confident INM-901 oral formulation can address these issues by achieving better absorption in the GI tract and in the blood stream, effectively penetrating the blood-brain barrier, in addition to ease of administration and higher accessibility to patients.
“We are excited by the recent data confirming that INM-901 can be delivered across the blood brain barrier to the brain tissue as an oral formulation which provides significant advantages for further development of this compound in the treatment of Alzheimer’s,” said Michael Woudenberg, InMed’s Chief Operating Officer and SVP of Chemistry, Manufacturing and Controls. “Similar drug levels in the target tissue are not usually seen between oral versus IP delivery. The supporting data generated by the oral formulation provides an attractive therapeutic approach given the many challenges associated with delivery of drug(s) to the brain.”
The company is already conducting further research for the drug candidate substance and the product formulation, including dose ranging, drug metabolism and pharmacokinetic studies in view of submitting INM-901 for investigational new drug status with the Food and Drug Administration.
The Alzheimer’s therapeutics market is projected to grow significantly in the coming years, driven by an aging global population and increasing prevalence of the disease. In 2022, the market was valued at $4.05 billion, and is expected to grow at a compound annual growth rate of 19.99% from 2023 to 2030, with a growing demand for effective therapies that can halt or slow the progression of the disease (https://nnw.fm/8EdFG ).
Given the current landscape, the positive preclinical results of INM-901 position InMed Pharmaceuticals as a potential leader in the development of promising, innovative treatments for Alzheimer’s. The formulation’s success could mark a significant advancement in Alzheimer’s care, offering hope to millions of patients worldwide.
For more information, visit the company’s website at www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://nnw.fm/INM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- INM-901 oral formulation shows encouraging results in preclinical studies
- High bioavailability of INM-901 oral formulation was shown to provide similar drug concentration levels in the brain as intraperitoneal injection
- Oral delivery method offers advantages such as lower treatment costs, in comparison with intravenous delivery of large molecule antibody therapies
- The company is conducting further research including drug metabolism studies, dose ranging studies and pharmacokinetic studies
InMed Pharmaceuticals (NASDAQ: INM), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors, announced that its drug candidate INM-901 as an oral formulation will be used in its development programs for Alzheimer’s disease following encouraging results obtained in preclinical trials (https://nnw.fm/xJETf ).
INM-901 is a small molecule drug candidate that demonstrated multiple pharmacological effects in preclinical studies including neuroprotective effects, extending the length of neurites which is important for brain cell-to-cell communication, as well as reducing neuroinflammation. These preclinical studies were conducted in well-characterized study models of Alzheimer’s disease.
Recent preclinical studies further showed that INM-901 can be administered orally, with the same therapeutic effects in the brain as intraperitoneal injections. INM-901 oral formulation was shown to maintain similar drug exposure levels as intraperitoneal injections over a 24-hour period. Oral delivery offers multiple advantages, including an overall reduction in treatment delivery costs compared to intravenous delivery of large molecule antibody therapies currently administered in such cases.
Large molecule antibody therapies are difficult to formulate orally and also present significant challenges to gastrointestinal tract absorption and further blood stream delivery, which is why IV or subcutaneous delivery methods need to be used instead. Additionally, large molecule therapies come with significant side effects, such as brain inflammation and bleeding, which requires constant monitoring and regular brain scans.
InMed Pharmaceuticals is confident INM-901 oral formulation can address these issues by achieving better absorption in the GI tract and in the blood stream, effectively penetrating the blood-brain barrier, in addition to ease of administration and higher accessibility to patients.
“We are excited by the recent data confirming that INM-901 can be delivered across the blood brain barrier to the brain tissue as an oral formulation which provides significant advantages for further development of this compound in the treatment of Alzheimer’s,” said Michael Woudenberg, InMed’s Chief Operating Officer and SVP of Chemistry, Manufacturing and Controls. “Similar drug levels in the target tissue are not usually seen between oral versus IP delivery. The supporting data generated by the oral formulation provides an attractive therapeutic approach given the many challenges associated with delivery of drug(s) to the brain.”
The company is already conducting further research for the drug candidate substance and the product formulation, including dose ranging, drug metabolism and pharmacokinetic studies in view of submitting INM-901 for investigational new drug status with the Food and Drug Administration.
The Alzheimer’s therapeutics market is projected to grow significantly in the coming years, driven by an aging global population and increasing prevalence of the disease. In 2022, the market was valued at $4.05 billion, and is expected to grow at a compound annual growth rate of 19.99% from 2023 to 2030, with a growing demand for effective therapies that can halt or slow the progression of the disease (https://nnw.fm/8EdFG ).
Given the current landscape, the positive preclinical results of INM-901 position InMed Pharmaceuticals as a potential leader in the development of promising, innovative treatments for Alzheimer’s. The formulation’s success could mark a significant advancement in Alzheimer’s care, offering hope to millions of patients worldwide.
For more information, visit the company’s website at www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://nnw.fm/INM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
